Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Svane

Showing results (751-760 of 811) with videos related to

Pageof 82
Sort By:
British Journal of Pharmacology|May 22, 2020
Effect of selective I<sub>K,ACh</sub> inhibition by XAF-1407 in an equine model of tachypacing-induced persistent atrial fibrillationMerle Friederike Fenner, Helena Carstensen, Sarah Dalgas Nissen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 10, 2025
Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin 2 in advanced cutaneous melanoma: a systematic review and meta-analysisS Martín-Lluesma, U Dafni, K Vervita, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 25, 2018
T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regressionR Andersen, T H Borch, A Draghi, et al.
Nature Communications|August 1, 2020
Escape from nonsense-mediated decay associates with anti-tumor immunogenicityKevin Litchfield, James L Reading, Emilia L Lim, et al.
Nature Medicine|December 10, 2021
A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanomaJulie Westerlin Kjeldsen, Cathrine Lund Lorentzen, Evelina Martinenaite, et al.
Journal for Immunotherapy of Cancer|February 26, 2025
Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020Paolo A Ascierto, Hao Tang, Sonia Dolfi, et al.
The Journal of Clinical Investigation|November 23, 2021
Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanomaNikolaj Pagh Kristensen, Christina Heeke, Siri A Tvingsholm, et al.
Cancer Immunology Research|July 4, 2019
MERTK Acts as a Costimulatory Receptor on Human CD8<sup>+</sup> T CellsMarlies J W Peeters, Donata Dulkeviciute, Arianna Draghi, et al.
Frontiers in Oncology|December 9, 2022
Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHVUffe Klausen, Jacob Handlos Grauslund, Nicolai Grønne Dahlager Jørgensen, et al.
Nature Communications|November 17, 2025
β-adrenergic signaling blockade attenuates metastasis through activation of cytotoxic CD4 T cellsKlaire Yixin Fjæstad, Astrid Zedlitz Johansen, Hannes Linder, et al.
Pageof 82

Showing results (751-760 of 811) with videos related to

Sort By:
Pageof 82
British Journal of Pharmacology|May 22, 2020
Effect of selective I<sub>K,ACh</sub> inhibition by XAF-1407 in an equine model of tachypacing-induced persistent atrial fibrillationMerle Friederike Fenner, Helena Carstensen, Sarah Dalgas Nissen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 10, 2025
Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin 2 in advanced cutaneous melanoma: a systematic review and meta-analysisS Martín-Lluesma, U Dafni, K Vervita, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 25, 2018
T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regressionR Andersen, T H Borch, A Draghi, et al.
Nature Communications|August 1, 2020
Escape from nonsense-mediated decay associates with anti-tumor immunogenicityKevin Litchfield, James L Reading, Emilia L Lim, et al.
Nature Medicine|December 10, 2021
A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanomaJulie Westerlin Kjeldsen, Cathrine Lund Lorentzen, Evelina Martinenaite, et al.
Journal for Immunotherapy of Cancer|February 26, 2025
Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020Paolo A Ascierto, Hao Tang, Sonia Dolfi, et al.
The Journal of Clinical Investigation|November 23, 2021
Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanomaNikolaj Pagh Kristensen, Christina Heeke, Siri A Tvingsholm, et al.
Cancer Immunology Research|July 4, 2019
MERTK Acts as a Costimulatory Receptor on Human CD8<sup>+</sup> T CellsMarlies J W Peeters, Donata Dulkeviciute, Arianna Draghi, et al.
Frontiers in Oncology|December 9, 2022
Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHVUffe Klausen, Jacob Handlos Grauslund, Nicolai Grønne Dahlager Jørgensen, et al.
Nature Communications|November 17, 2025
β-adrenergic signaling blockade attenuates metastasis through activation of cytotoxic CD4 T cellsKlaire Yixin Fjæstad, Astrid Zedlitz Johansen, Hannes Linder, et al.
Pageof 82